Literature DB >> 23398052

Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates.

David Hui1, Margarita Morgado, Marieberta Vidal, Laura Withers, Quan Nguyen, Gary Chisholm, Clarence Finch, Eduardo Bruera.   

Abstract

BACKGROUND AND
OBJECTIVE: It is unclear if physiologic measures are useful for assessing dyspnea. We examined the association among the subjective rating of dyspnea according to patients with advanced cancer, caregivers and nurses, and various physiologic measures.
METHODS: We conducted a cross-sectional survey of patients with cancer hospitalized at MD Anderson Cancer Center. We asked patients, caregivers, and nurses to assess the patients' dyspnea at the time of study enrollment independently using a numeric rating scale (0=none, 10=worst). Edmonton Symptom Assessment Scale (ESAS) ratings, causes of dyspnea, vitals, and Respiratory Distress Observation Scale [RDOS] ratings were collected.
RESULTS: A total of 299 patients were enrolled in the study: average age 62 (range 20-98), female 47%, lung cancer 37%, and oxygen use 57%. The median RDOS rating was 2/16 (interquartile range 1-3) and the number of potential causes was 3 (range 2-4), with pleural effusion (n=166, 56%), pneumonia (n=144, 48%), and lung metastasis (n=125, 42%) being the most common. The median intensity of patients' dyspnea at the time of assessment was 3 (interquartile range 0-6) for patients, 4 (interquartile range 1-6) for caregivers, and 2 (interquartile range 0-3) for bedside nurses. Patients' expression of dyspnea correlated moderately with caregivers' (r=0.68, p<0.001) and nurses' (r=0.50, p<0.001) assessments, and weakly with RDOS (r=0.35, p<0.001), oxygen level (r=0.32, p<0.001), and the number of potential causes (r=0.19, p=0.001). In multivariate analysis, patients' dyspnea was only independently associated with ESAS dyspnea (p=0.002) and dyspnea as assessed by caregivers (p<0.001).
CONCLUSION: Patients' level of dyspnea was weakly associated with physiologic measures. Caregivers' perception may be a useful surrogate for dyspnea assessment.

Entities:  

Mesh:

Year:  2013        PMID: 23398052      PMCID: PMC3583248          DOI: 10.1089/jpm.2012.0364

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  35 in total

1.  The origin of the sensations of dyspnea.

Authors:  G W WRIGHT; B V BRANSCOMB
Journal:  Trans Am Clin Climatol Assoc       Date:  1954

2.  Discrepancies and similarities in how patients with lung cancer and their professional and family caregivers assess symptom occurrence and symptom distress.

Authors:  Eva Broberger; Carol Tishelman; Louise von Essen
Journal:  J Pain Symptom Manage       Date:  2005-06       Impact factor: 3.612

Review 3.  Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Validity of the numeric rating scale as a measure of dyspnea.

Authors:  A G Gift; G Narsavage
Journal:  Am J Crit Care       Date:  1998-05       Impact factor: 2.228

5.  Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life.

Authors:  Kwok Oi-Ling; Doris T S E Man-Wah; Daniel N G Kam-Hung
Journal:  Palliat Med       Date:  2005-04       Impact factor: 4.762

Review 6.  Management of dyspnea in advanced cancer patients.

Authors:  C Ripamonti
Journal:  Support Care Cancer       Date:  1999-07       Impact factor: 3.603

7.  The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.

Authors:  E Bruera; N Kuehn; M J Miller; P Selmser; K Macmillan
Journal:  J Palliat Care       Date:  1991       Impact factor: 2.250

8.  A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease.

Authors:  Joao Paulo Solano; Barbara Gomes; Irene J Higginson
Journal:  J Pain Symptom Manage       Date:  2006-01       Impact factor: 3.612

9.  Asking the right question of informal caregivers about patient symptom experiences: multiple proxy perspectives and reducing interrater gap.

Authors:  Michelle M Lobchuk; Susan E McClement; Paul J Daeninck; Christopher Shay; Heather Elands
Journal:  J Pain Symptom Manage       Date:  2007-02       Impact factor: 3.612

10.  Dyspnea, anxiety, and depression in chronic respiratory impairment.

Authors:  R Kellner; J Samet; D Pathak
Journal:  Gen Hosp Psychiatry       Date:  1992-01       Impact factor: 3.238

View more
  22 in total

1.  Intensity cut-points for the Respiratory Distress Observation Scale.

Authors:  Margaret L Campbell; Thomas N Templin
Journal:  Palliat Med       Date:  2015-01-29       Impact factor: 4.762

2.  Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Minjeong Park; Janet Williams; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-07-09       Impact factor: 3.612

3.  Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Diane Liu; Diwakar D Balachandran; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2017-08-10       Impact factor: 3.612

4.  Management of dyspnea in palliative care.

Authors:  A M Crombeen; E J Lilly
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

5.  Impact of dyspnea on advanced cancer patients referred to a palliative radiotherapy clinic.

Authors:  Leigha Rowbottom; Stephanie Chan; Liying Zhang; Rachel McDonald; Elizabeth Barnes; May Tsao; Pearl Zaki; Edward Chow
Journal:  Support Care Cancer       Date:  2017-03-24       Impact factor: 3.603

6.  The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.

Authors:  David Hui; Kenneth Hess; Seyedeh S Dibaj; Joseph Arthur; Rony Dev; Shalini Dalal; Suresh Reddy; Eduardo Bruera
Journal:  Cancer       Date:  2018-02-22       Impact factor: 6.860

7.  Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.

Authors:  David Hui; Angela Xu; Susan Frisbee-Hume; Gary Chisholm; Margarita Morgado; Suresh Reddy; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2013-07-03       Impact factor: 3.612

Review 8.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

9.  Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Anne Tsao; Marvin Delgado Guay; Charles Lu; William William; Katherine Pisters; George Eapen; Frank Fossella; Sapna Amin; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-06-18       Impact factor: 3.612

10.  Symptom Expression in the Last Seven Days of Life Among Cancer Patients Admitted to Acute Palliative Care Units.

Authors:  David Hui; Renata dos Santos; Gary B Chisholm; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2014-09-19       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.